Pasithea Therapeutics announced its participation as an exhibitor at the Children's Tumor Foundation 2026 NF Conference in Denver, focusing on its lead drug candidate PAS-004 for treating neurofibromatosis type 1 (NF1). PAS-004, a next-generation MEK inhibitor, recently received FDA Fast Track and Rare Pediatric Disease designations, highlighting its potential to address NF1-associated plexiform neurofibromas. The company is conducting Phase 1 trials for PAS-004 in both advanced cancer and NF1 patients, aiming to develop safer, long-term therapies. Engagement with the NF1 community at the conference supports Pasithea's mission to improve patient outcomes through collaboration and innovation.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Experian PLC started its 2027 financial year with a 10% revenue increase in the first quarter, driven by strong demand in North America and Latin America. Organic growth was 7%, with North America growing 7% despite a 2% drop in consumer services due...
Gooch & Housego, a UK-listed photonics company specializing in precision optics for aerospace and defence, has agreed to a £345.6 million takeover by US private equity firm Arlington Capital Partners. The offer values the company at a 41.3% premium t...
Aave DAO has proposed an innovative mobile app that integrates fiat currency deposits, self-custody, and decentralized finance (DeFi) lending in one platform. This app allows users to convert fiat to stablecoins and earn yields without needing extern...
Analysts expect Netflix to report $12.6 billion in revenue for Q2 and $51.3 billion for the full year 2026. The operating margin forecast has been revised down from 33% to 32% due to anticipated higher expenses, with an expected operating profit of $...
